XellSmart’s universal cell therapy drug for Parkinson’s disease receives Fast Track designation from the US FDA
On July 28, 2026, XellSmart Bio‘s independently developed allogeneic universal “off-the-shelf” XS411 cell therapy injection, for the treatment of Parkinson’s disease, the world’s second most prevalent neurodegenerative…